Johnson & Johnson will soon start testing its COVID-19 vaccine candidate in U.S. adolescents, the company announced Friday. The company plans to begin testing the vaccine in a small number of 16 and 17 year olds as part of an ongoing Phase 2 trial for adults, gradually expanding the trial to children aged 12-17 after reviewing the initial data.

It is currently enrolling adolescents in Spain and the United Kingdom and expects to start enrolling them soon in the U.S., Netherlands and Canada, followed by Brazil and Argentina.

In February, the U.S. Food and Drug Administration authorized emergency use of the vaccine for individuals 18 and older. 

Related News Articles

Headline
The Centers for Disease Control and Prevention yesterday recommended children age 5-11 receive a booster dose five months after completing the Pfizer COVID-19…
Headline
Learn how Loyola University Health System’s pop-up COVID-19 testing laboratory broadened collaboration between clinicians and hospital leadership, improved…
Headline
The Biden Administration plans to continue the COVID-19 public health emergency beyond July 15, administration officials told CNN this week. The…
Headline
U.S. residents can order online eight more free at-home tests for COVID-19, the White House announced yesterday. People who have difficulty accessing the…
Headline
The Food and Drug Administration today authorized a single Pfizer COVID-19 booster dose for children aged 5-11 who completed the Pfizer vaccine primary series…
Headline
A recent op-ed in the online publication STAT contains “blatant factual inaccuracies” and omits critical information about hospital and health systems’…